Gene info: ID 54207

Gene: KCNK10

GENE ID: 54207

Synonyms: K2p10.1|PPP1R97|TREK-2|TREK2

Description: potassium two pore domain channel subfamily K member 10

Gene type: protein-coding

Location: 14q31.3

dbXrefs: Ensembl:ENSG00000100433 MIM:605873 Vega:OTTHUMG00000170743 UniprotKB:P57789

RefSeq: NC_000014.9

Retrived from: SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: AD

# Publications: 0

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 3.246e-1 (AD) 6.638e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs11849247	chr14:88242159 (GRCh38.p7)	T>C	alcohol dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
DIP2B	0.72
SVEP1	0.701
UVRAG	0.695
NXPE3	0.694
KIAA1324L	0.679
SESTD1	0.673
L3MBTL4	0.661
FLNB	0.659
STARD13	0.658
ENOX2	0.657

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PPP1R3G	-0.403
WNT7B	-0.393
EYA2	-0.391
KCNJ16	-0.39
RXRG	-0.361
PPP1R3C	-0.339
RLBP1	-0.338
DIAPH3	-0.325
PIPOX	-0.324
RNF43	-0.324

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C006718	1,12-benzoperylene	"1,12-benzoperylene results in increased expression of KCNK10 mRNA"	26377693
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
D020106	Acrylamide	Acrylamide results in decreased expression of KCNK10 mRNA	28959563
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of KCNK10 gene	27153756
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of KCNK10 mRNA	16483693
D016718	Arachidonic Acid	Arachidonic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
C006780	bisphenol A	bisphenol A results in decreased expression of KCNK10 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of KCNK10 gene	28505145
C018475	butyraldehyde	butyraldehyde results in increased expression of KCNK10 mRNA	26079696
D020245	p-Chloromercuribenzoic Acid	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in decreased expression of KCNK10 mRNA	26272509
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KCNK10 gene	20938992
D016572	Cyclosporine	Cyclosporine results in decreased methylation of KCNK10 promoter	27989131
D004110	Diltiazem	Diltiazem inhibits the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
C118739	entinostat	entinostat results in decreased expression of KCNK10 mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of KCNK10 mRNA	29097150
D005419	Flavonoids	Flavonoids results in decreased expression of KCNK10 mRNA	18035473
D005439	Flufenamic Acid	Flufenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
D005473	Fluoxetine	Fluoxetine results in decreased activity of KCNK10 protein	23022515
D005473	Fluoxetine	Fluoxetine results in increased expression of KCNK10 mRNA	23022515
D005473	Fluoxetine	KCNK10 mRNA affects the susceptibility to Fluoxetine	23022515
D005473	Fluoxetine	[KCNK2 mRNA co-treated with KCNK10 mRNA] affects the susceptibility to Fluoxetine	23022515
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KCNK10 gene	20938992
C039281	furan	furan results in decreased expression of KCNK10 mRNA	24183702
C004312	glycidol	glycidol results in decreased expression of KCNK10 mRNA	24915197
D006221	Halothane	Halothane promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of KCNK10 mRNA	26752646
D008528	Mefenamic Acid	Mefenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
C042720	mercuric bromide	mercuric bromide results in decreased expression of KCNK10 mRNA	26272509
C042720	mercuric bromide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KCNK10 gene	20938992
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of KCNK10 mRNA	28001369
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in decreased expression of KCNK10 mRNA	24810058
C406082	monomethylarsonous acid	[monomethylarsonous acid affects the acetylation of HIST3H3 protein] which affects the methylation of KCNK10 promoter	18448484
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of KCNK10 mRNA"	25620056
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of KCNK10 mRNA"	25620056
D009544	Niflumic Acid	Niflumic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C496932	panobinostat	panobinostat results in decreased expression of KCNK10 mRNA	26272509
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of KCNK10 mRNA	26272509
C006253	pirinixic acid	pirinixic acid results in increased expression of KCNK10 mRNA	20813756
D011188	Potassium	Arachidonic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
D011188	Potassium	Diltiazem inhibits the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
D011188	Potassium	Flufenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
D011188	Potassium	Halothane promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
D011188	Potassium	Mefenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
D011188	Potassium	Niflumic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]	16075240
D011441	Propylthiouracil	Propylthiouracil results in increased expression of KCNK10 mRNA	24780913
C017947	sodium arsenite	[sodium arsenite affects the acetylation of HIST3H3 protein] which affects the methylation of KCNK10 promoter	18448484
C017947	sodium arsenite	sodium arsenite affects the methylation of KCNK10 gene	28589171
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of KCNK10 mRNA	26377647
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
C012589	trichostatin A	trichostatin A results in decreased expression of KCNK10 mRNA	24935251\|2627250
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of KCNK10 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of KCNK10 mRNA	23179753\|2438349
D014635	Valproic Acid	Valproic Acid results in increased expression of KCNK10 mRNA	23179753
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of KCNK10 gene	25560391

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005244	voltage-gated ion channel activity	-	IEA	-
GO:0005267	potassium channel activity	-	TAS	10880510
GO:0022841	potassium ion leak channel activity	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0007165	signal transduction	-	NAS	10880510
GO:0007613	memory	-	IEA	-
GO:0030322	stabilization of membrane potential	-	IBA	21873635
GO:0034765	regulation of ion transmembrane transport	-	IEA	-
GO:0071805	potassium ion transmembrane transport	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IBA	21873635

KEGG ID	KEGG Term
hsa04971	Gastric acid secretion

Reactome ID	Reactome Term	Evidence
R-HSA-112316	Neuronal System	TAS
R-HSA-1296071	Potassium Channels	TAS
R-HSA-1296346	Tandem pore domain potassium channels	TAS
R-HSA-1299503	TWIK related potassium channel (TREK)	TAS
R-HSA-397014	Muscle contraction	TAS
R-HSA-5576886	Phase 4 - resting membrane potential	TAS
R-HSA-5576891	Cardiac conduction	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal